This Isn't Experimental: Vitamin K2 Kills Cancer — But Only at This Dose | Cancer Drug Designer

Summary

Key Points

• The video investigates the claim that vitamin K2 can kill prostate cancer cells, stressing the importance of scientific validation and precise dosing to avoid wasting time and resources. 2:01
• While prostate cancer is responsive, blood cancers (leukemias, myelomas, B-cell lymphomas), colorectal, and lung cancers demonstrate the highest sensitivity to vitamin K2, with most cancer cells dying at concentrations between 25 and 50 micromolar. 3:27
• Extensive cell line research, consistently replicated across many labs and cancer types, indicates that vitamin K2 is cytotoxic, meaning it directly kills cancer cells rather than just slowing their growth. 4:14
• The cytotoxic effects of vitamin K2 occur rapidly, typically within two to three days, suggesting its potential as a short-burst or pulse treatment rather than a long-term daily regimen. 4:52
• Human studies are scarce, but three well-conducted trials showed that 45 mg of vitamin K2 daily significantly reduced recurrence rates in liver cancer patients after tumor removal or ablation. 7:09
• Vitamin K3 is more potent in lab studies but is not recommended due to its significant risk of causing hemolytic anemia, a condition where red blood cells rupture. 7:55
• Achieving the effective concentration of 50 micromolar in humans requires a daily intake of 111 mg of vitamin K2, which translates to an impractical number of standard supplement capsules. 8:42
• Despite the high dosage, vitamin K2 is surprisingly safe, especially when taken with fat, making a short-pulse therapy (e.g., three days a month) a more practical approach than continuous daily intake. 10:14
• Vitamin K2 may be a worthwhile exploration for leukemias, liver, colorectal, lung, pancreatic, and prostate cancers, but it is likely ineffective for cholangiocarcinoma or glioblastoma. 10:27